Bicocca Open Archive

Logo unimib boa

Zerbato, B., Brancato, V., Lattuada, C., La Chimia, M., Scumaci, D., Chiaradonna, F. (2024). Hexosamine biosynthetic pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage. In Mining biochemistry for human health and well-being, 48th FEBS Congress, 29 June–3 July 2024, Milano, Italy (pp.81-81). WILEY.

Hexosamine biosynthetic pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage

Zerbato, B;Brancato, V;Chiaradonna, F
2024
abstract
Cancer metabolism, HBP, FR054, DNA damage
English
48th FEBS Congress
2024
Mining biochemistry for human health and well-being, 48th FEBS Congress, 29 June–3 July 2024, Milano, Italy
FEBS OPEN BIO
2024
14
S2
81
81
SpT-26-6
https://febs.onlinelibrary.wiley.com/doi/10.1002/2211-5463.13836
none
Zerbato, B., Brancato, V., Lattuada, C., La Chimia, M., Scumaci, D., Chiaradonna, F. (2024). Hexosamine biosynthetic pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage. In Mining biochemistry for human health and well-being, 48th FEBS Congress, 29 June–3 July 2024, Milano, Italy (pp.81-81). WILEY.
02 - Intervento a convegno
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/576761
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
Social impact